Direct medical costs of serious gastrointestinal ulcers attributable to non steroidal anti-inflammatory drugs in the Netherlands

Harald E. Vonkeman, Rogier M. Klok, Maarten J. Postma, Jacobus R.B.J. Brouwers, Mart A.F.J. van de Laar

Research output: Contribution to conferencePosterOther research output

9 Downloads (Pure)

Abstract

Purpose: The occurrence and prevention of gastrointestinal ulcers attributable to the use of non-steroidal anti-inflammatory drugs (NSAIDs) has become a major health care issue. Analysis of cost effectiveness of preventive strategies has been hampered by a lack of recent cost of illness studies. The aim of this study was to determine direct medical costs of serious gastrointestinal ulcers attributable to NSAIDs from the societal perspective

Methods: From November 2001 until December 2003 all consecutive patients who were hospitalized due to gastropathy attributable to NSAIDs (serious event) were identified. Data was retrieved on the number of days hospitalized, and on the number and type of diagnostic and therapeutic interventions. Direct costs of resources used per patient were estimated. A bootstrap procedure of 10.000 replicates was performed to estimate means and 95% confidence interval of the total direct costs.

Results: During the observational period 104 patients from a cohort of 152.989 inhabitants were hospitalized with NSAID-gastropathy (incidence 0.314 per 1000 persons per year). Most patients were elderly (mean 70.4 years, SD 16.7). Many patients reported serious, especially cardiovascular, co-morbidity. Mortality was high; 11 (10.6%) died in the hospital, and another 4 (3.8%) died within 3 months. Direct medical costs were € 8.375 (95% CI € 7.067 - € 10.393). In extrapolation to The Netherlands, annually approximately 5.105 people are hospitalized, with an estimated 541 deaths directly, and another 194 indirectly due to NSAID-gastropathy. The total annual Dutch direct medical costs for serious NSAID related gastropathy would be € 42.754.375 (95% CI € 36.077.035 - € 53.056.265).

Conclusion: Clinically relevant NSAID-gastropathy has an in hospital mortality rate of 10.6%. Direct medical costs for Dutch society are approximately € 42.750.000.
Original languageEnglish
Pages-
Number of pages1
Publication statusPublished - 10 Nov 2006
EventACR/ARHP Annual Scientific Meeting 2006 - Washington DC Convention Center, Washington, United States
Duration: 10 Nov 200615 Nov 2006

Conference

ConferenceACR/ARHP Annual Scientific Meeting 2006
CountryUnited States
CityWashington
Period10/11/0615/11/06
Other70th Annual Meeting of the AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) including the 41st Annual Meeting of the ASSOCIATION OF RHEUMATOLOGY HEALTH PROFESSIONALS

Keywords

  • METIS-235553
  • IR-101838

Fingerprint

Dive into the research topics of 'Direct medical costs of serious gastrointestinal ulcers attributable to non steroidal anti-inflammatory drugs in the Netherlands'. Together they form a unique fingerprint.

Cite this